These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. [Comprehensive care of patients with thrombocythemia]. Hrubisková K; Steruská M; Horváth A Vnitr Lek; 1987 Oct; 33(10):872-82. PubMed ID: 3479860 [No Abstract] [Full Text] [Related]
7. Megakaryoblastic termination of myeloproliferative disorders. Amin MB; Maeda K; Carey JL; Babu RV; Raman BK Henry Ford Hosp Med J; 1992; 40(1-2):122-6. PubMed ID: 1428963 [TBL] [Abstract][Full Text] [Related]
8. The spleen in myeloproliferative disorders. Goldman JM; Nolasco I Clin Haematol; 1983 Jun; 12(2):505-16. PubMed ID: 6352114 [No Abstract] [Full Text] [Related]
9. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders]. Bettini R; Marzetta K; Miglioranza A; Redaelli S; Maino C; Maffiolini A; Gorini M Recenti Prog Med; 2003; 94(7-8):314-20. PubMed ID: 12868237 [TBL] [Abstract][Full Text] [Related]
11. De novo appearance of der(1;7)(q10;p10) is associated with leukemic transformation and unfavorable prognosis in essential thrombocythemia. Hsiao HH; Ito Y; Sashida G; Ohyashiki JH; Ohyashiki K Leuk Res; 2005 Nov; 29(11):1247-52. PubMed ID: 16164981 [TBL] [Abstract][Full Text] [Related]